6.2 Non-Sterile Compounding (USP 795 & GA Board Rules)

Non-Sterile Compounding (USP 795 & GA Board Rules)

Introduction to USP Chapter 795

Non-sterile compounding is a fundamental aspect of pharmacy practice that involves the creation of customized medication preparations that do not require absolute sterility. This includes the formulation of oral liquids, topical creams, ointments, suppositories, and capsules tailored to meet the specific medical needs of an individual patient. In the state of Georgia, the practice of non-sterile compounding is stringently regulated by the Georgia Board of Pharmacy, which heavily incorporates and enforces the standards set forth in the United States Pharmacopeia (USP) Chapter 795. USP 795 provides the comprehensive framework and minimum standards necessary to ensure the quality, safety, and integrity of non-sterile compounded preparations. The primary objective of these regulations is to protect patients from harm that could result from sub-potent, super-potent, contaminated, or otherwise improperly formulated medications. For the MPJE, candidates must possess a rigorous understanding of the distinctions between compounding and manufacturing, the required facility specifications, personnel training mandates, and the critical rules governing Beyond-Use Dates (BUDs). The Georgia Board expects all compounding pharmacies to maintain a state of continuous compliance, and failure to adhere to USP 795 standards can lead to severe disciplinary actions, including the suspension of compounding privileges and heavy fines.

Facility and Equipment Requirements

To ensure a safe and controlled environment for the preparation of medications, USP 795 mandates specific facility and equipment standards for non-sterile compounding. The compounding area must be a designated space that is distinctly separate from the routine dispensing and counseling areas of the pharmacy. This separation is crucial to minimize distractions, reduce the risk of cross-contamination, and ensure that the compounding process occurs in a dedicated, controlled environment. The facility must be well-lit, properly ventilated, and maintained in a clean and sanitary condition at all times. All surfaces within the compounding area, including countertops, floors, and shelving, must be smooth, impervious, and easily cleanable to prevent the accumulation of dust, debris, and potential contaminants.

Adequate plumbing is essential, and the compounding area must be equipped with a sink that provides both hot and cold running water. This sink is not only for handwashing but also for the cleaning of compounding equipment. The equipment used in the compounding process, such as balances, mortars and pestles, spatulas, and graduated cylinders, must be of appropriate design and capacity for the intended preparations. Furthermore, all equipment must be routinely inspected, calibrated, and maintained according to the manufacturer's specifications to ensure accuracy and reliability. A documented schedule for equipment maintenance and calibration must be kept on file and readily accessible for inspection by the Board of Pharmacy.

Personnel Training and Garbing

The individuals performing the compounding are the most critical factor in ensuring the quality of the final preparation. Therefore, USP 795 requires that all compounding personnel receive rigorous and ongoing training. Before an individual is permitted to compound any preparation, they must demonstrate proficiency in the specific compounding techniques, equipment operation, and safety procedures required for that task. This training must be thoroughly documented, and personnel must undergo regular performance evaluations to verify their continued competence.

Proper garbing is essential to protect both the compounding personnel from potential exposure to active pharmaceutical ingredients (APIs) and the compounded preparation from contamination originating from the personnel. The required garb depends on the nature of the preparation but typically includes a clean laboratory coat or gown, gloves, a face mask, and a hairnet. In certain situations, such as when handling powders that may generate dust, additional protective equipment like safety goggles or a specialized respirator may be necessary. Personnel must adhere to strict hand hygiene protocols, washing their hands and forearms thoroughly with antimicrobial soap and water before donning gloves and beginning the compounding process.

Beyond-Use Dates (BUDs) for Non-Sterile Preparations

One of the most heavily tested concepts on the MPJE regarding non-sterile compounding is the assignment of Beyond-Use Dates (BUDs). A BUD is the date after which a compounded preparation shall not be used; it is determined from the date the preparation is compounded. The assignment of a BUD is a critical safety measure designed to ensure that the patient receives a medication that maintains its expected potency and has not degraded or grown harmful microorganisms. USP 795 establishes strict maximum BUD limits based primarily on the presence or absence of water in the formulation.

For non-aqueous formulations (those that contain no water, such as an ointment composed entirely of petroleum jelly or a powder-filled capsule), the maximum BUD is the earliest expiration date of any active pharmaceutical ingredient (API) used in the preparation, or six months (180 days), whichever is earlier.

For water-containing oral formulations (such as an oral liquid suspension formulated in a water-based syrup), the maximum BUD is strictly limited to 14 days. Furthermore, these preparations must be stored at controlled cold temperatures (refrigerated) to inhibit microbial growth.

For water-containing topical/dermal and mucosal liquid and semisolid formulations (such as a cream or gel intended for application to the skin or mucous membranes), the maximum BUD is 30 days. These preparations may typically be stored at controlled room temperature, depending on the specific ingredients.

It is crucial to understand that these are maximum limits. If any ingredient in the preparation has an expiration date that is shorter than the USP-defined maximum BUD, the shorter date must be assigned. Additionally, a pharmacist may assign a longer BUD if there is valid, specific scientific stability data (from a peer-reviewed journal or analytical testing) that supports the extended date for that exact formulation.

Documentation: Master Formulation and Compounding Records

Meticulous documentation is the backbone of quality assurance in compounding. USP 795 mandates the use of two distinct types of records for every compounded preparation: the Master Formulation Record and the Compounding Record.

The Master Formulation Record acts as the definitive recipe or blueprint for a specific compounded preparation. It is created once and must contain detailed information, including the official name of the preparation, the strength and dosage form, a complete list of all ingredients with their expected quantities, the exact step-by-step compounding procedure, the necessary equipment, mixing instructions (including specific times and speeds), the assigned BUD, and the required labeling information. This record ensures that the preparation can be replicated consistently and accurately every time it is needed.

The Compounding Record is the specific log or diary created every single time a preparation is compounded. It must reference the Master Formulation Record and document the specific details of that exact batch. The Compounding Record must include the name of the preparation, the Master Formulation Record reference number, the date and time of compounding, the identity of the person who compounded it, the identity of the pharmacist who performed the final verification, the specific lot numbers and expiration dates of all ingredients used, the actual quantities measured, the total quantity compounded, the assigned BUD, and the unique prescription or lot number assigned to the final product. This record provides a complete audit trail, allowing a pharmacy to trace a specific patient's medication back to the exact ingredients and procedures used on that specific day.

Table: Maximum Beyond-Use Dates (BUDs) per USP 795